April 3, 2017
Combating biosimilars

Combating biosimilars – Rituxan

The Oncologic Drugs Advisory Committee (ODAC) of FDA has unanimously recommended approval of subcutaneous (SC) rituximab for the treatment of patients with certain blood cancers. A final approval to this effect is expected by June 26, 2017 (Official Announcement). The approval of SC formulation certainly has its benefits such as, […]
March 31, 2017
Biosim go to market strategy

Biosimilar go-to-market strategy

Commercialization is the next frontier for biosimilar developers. As more and more biosimilars are gaining regulatory approvals, the discussion on commercial aspects of the yet evolving market is gaining momentum. Biosimilar commercialization will have its very specific attributes and nuances. Biosimilars are neither first- nor best- in class products, these […]